Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

Y-MABS THERAPEUTICS, INC.

(YMAB)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/20/2021 10/21/2021 10/22/2021 10/25/2021 10/26/2021 Date
26.14(c) 26.27(c) 26.55(c) 25.91(c) 25.45(c) Last
66 877 78 698 101 879 109 193 133 550 Volume
-1.21% +0.50% +1.07% -2.41% -1.78% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 71,5 M - -
Net income 2021 -42,6 M - -
Net cash position 2021 83,9 M - -
P/E ratio 2021 -29,6x
Yield 2021 -
Sales 2022 120 M - -
Net income 2022 -40,8 M - -
Net cash position 2022 349 M - -
P/E ratio 2022 -28,4x
Yield 2022 -
Capitalization 1 109 M 1 109 M -
EV / Sales 2021 14,3x
EV / Sales 2022 6,34x
Nbr of Employees 125
Free-Float 83,7%
More Financials
Company
Y-mAbs Therapeutics, Inc. is a commercial-stage clinical biopharmaceutical company. The Company is focused on the development and commercialization of novel, antibody based therapeutic products for the treatment of cancer. Its product pipeline includes DANYELZA (naxitamab-gqgk), which is a humanized monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor, or GM-CSF,for the treatment... 
More about the company
Ratings of Y-mAbs Therapeutics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about Y-MABS THERAPEUTICS, INC.
10/19INSIDER SELL : Y-mabs Therapeutics
MT
10/08Y MABS THERAPEUTICS : mAbs 177Lu-omburtamab-DTPA for the Treatment of Patients with Medull..
AQ
10/07Y MABS THERAPEUTICS : Gets FDA's Rare Pediatric Disease Designation for Potential Therapy ..
MT
10/07Y MABS THERAPEUTICS : mAbs' 177Lu-omburtamab-DTPA for the Treatment of Patients with Medul..
PU
10/07Y-MABS THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
10/07Y MABS THERAPEUTICS : mAbs' 177Lu-omburtamab-DTPA for the Treatment of Patients with Medul..
AQ
10/07U.S. Food and Drug Administration Grants Rare Pediatric Disease Designation for Y-mAbs’..
CI
10/04INSIDER SELL : Y-mabs Therapeutics
MT
09/23INSIDER SELL : Y-mabs Therapeutics
MT
09/16Y MABS THERAPEUTICS : mAbs Announces Data to be Presented at SIOP 2021
AQ
09/14Y MABS THERAPEUTICS : mAbs Announces Priorit Review of BLA for DANELZA (naxitamab-gqgk) in..
AQ
09/13Y MABS THERAPEUTICS : mAbs-Licensed Danelza Granted Priorit Review b Chinese Regulator; Sh..
MT
09/13Y MABS THERAPEUTICS : mAbs Announces Priorit Review of BLA for DANELZA« (naxitamab-gqgk) i..
PU
09/13Y MABS THERAPEUTICS : mAbs to Host Ke Opinion Leader Webinar on DANELZA (naxitamab-gqgk) F..
AQ
09/13Y-MABS THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
More news
News in other languages on Y-MABS THERAPEUTICS, INC.
10/07Y-mAbs Therapeutics obtient de la FDA la désignation de maladie pédiatrique rare pour l..
09/13Danyelza, le produit sous licence de Y-mAbs, bénéficie d'une évaluation prioritaire de ..
More news
Analyst Recommendations on Y-MABS THERAPEUTICS, INC.
More recommendations
Chart Y-MABS THERAPEUTICS, INC.
Duration : Period :
Y-mAbs Therapeutics, Inc. Technical Analysis Chart | YMAB | US9842411095 | MarketScreener
Technical analysis trends Y-MABS THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 25,45 $
Average target price 55,33 $
Spread / Average Target 117%
EPS Revisions
Managers and Directors
Claus Juan M°ller-San Pedro Chief Executive Officer & Director
Thomas Gad Chairman, President & Head-Business Development
Bo Kruse CFO, Secretary. Treasurer & Executive VP
Torben Lund-Hansen Chief Technology Officer & Senior Vice President
Steen Lisby Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
Y-MABS THERAPEUTICS, INC.-48.60%1 109
GILEAD SCIENCES, INC.16.25%84 921
BIONTECH SE258.67%70 618
WUXI APPTEC CO., LTD.23.63%64 231
REGENERON PHARMACEUTICALS22.57%61 565
VERTEX PHARMACEUTICALS-22.12%47 753